GSK's shingles vaccine begins Phase III studies
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.